p53 mutation, but not in vitro predictor genes of therapeutic efficacy of cisplatin, is clinically relevant in comparing partial and complete responder cases of maxillary squamous cell carcinoma

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 851-856

  Kudo, Itsuhiro ^a   Esumi, Mariko ^a   Kida, Akihiro ^a   Ikeda, Minoru ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Drug resistance; Maxillary squamous cell carcinoma; p53 mutation

Indexed keywords

BCL2 RELATED PROTEIN A1; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P53; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MALE; MAXILLA; MAXILLA CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 77957376774     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.851     Document Type: Article

References (19)

1. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
2. Kamarajan P, Sun NK, Sun CL and Chao CC: Apaf-1 overexpression partially overcomes apoptotic resistance in a cisplatinselected HeLa cell line. FEBS Lett 505: 206-212, 2001.
3. Tanabe M, Izumi H, Ise T, et al: Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res 63: 8592-8595, 2003.
4. Wu X, Fan W, Xu S and Zhou Y: Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res 9: 5874-5879, 2003.
5. Yoo BC, Ku JL, Hong SH, et al: Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer 108: 532-539, 2004.
6. Cho HJ, Kim JK, Kim KD, et al: Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 237: 56-66, 2006.
7. Mangala LS, Zuzel V, Schmandt R, et al: Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 15: 3770-3780, 2009.
8. Olaussen KA, Mountzios G and Soria JC: ERCC1 as a risk stratifier in platinum-based chemotherapy for non-small-cell lung cancer. Curr Opin Pulm Med 13: 284-289, 2007.
9. Sugimoto C, Fujieda S, Seki M, et al: Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo. Int J Cancer 82: 860-867, 1999.
10. Fujieda S, Sunaga H, Tsuzuki H, et al: Expression of fas (CD95) ligand is correlated with IL-10 and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma. Cancer Lett 161: 73-81, 2000.
11. Miyazaki T, Kato H, Faried A, et al: Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. Anticancer Res 25: 2749-2755, 2005.
12. Sobin L and Wittekind C: TNM Classification of Malignant Tumours. 6th edition. Wiley-Liss, New York, 2002.
13. Shaulsky G, Goldfinger N, Tosky MS, Levine AJ and Rotter V: Nuclear localization is essential for the activity of p53 protein. Oncogene 6: 2055-2065, 1991.
14. Mandic R, Schamberger CJ, Muller JF, et al: Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin Cancer Res 11: 6845-6852, 2005.
15. Sakai E, Rikimaru K, Ueda M, et al: The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Int J Cancer 52: 867-872, 1992.
16. Cabelguenne A, Blons H, de Waziers I, et al: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18: 1465-1473, 2000.
17. Weber A, Bellmann U, Bootz F, Wittekind C and Tannapfel A: INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck. Virchows Arch 441: 133-142, 2002. (Pubitemid 34983979)
18. Eriksen JG, Alsner J, Steiniche T and Overgaard J: The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. Radiother Oncol 76: 135-142, 2005.
19. Bosch FX, Ritter D, Enders C, et al: Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer 111: 530-538, 2004.